Edoxaban Krka
Direct Oral Anticoagulant (DOAC) – Factor Xa Inhibitor
Edoxaban Krka is a generic version of edoxaban, a direct oral anticoagulant (DOAC) that works by selectively inhibiting coagulation factor Xa. It is prescribed to reduce the risk of stroke and systemic embolism in patients with non-valvular atrial fibrillation, and for the treatment and prevention of recurrent deep vein thrombosis (DVT) and pulmonary embolism (PE). Unlike warfarin, edoxaban requires no routine blood monitoring and has fewer dietary restrictions.
Quick Facts
Key Takeaways
- Edoxaban Krka is a once-daily oral anticoagulant that prevents blood clots by directly inhibiting factor Xa in the coagulation cascade.
- It is primarily prescribed for stroke prevention in non-valvular atrial fibrillation and for treating/preventing deep vein thrombosis and pulmonary embolism.
- Unlike warfarin, edoxaban does not require regular INR blood monitoring and has predictable pharmacokinetics with fewer food interactions.
- The most important risk is bleeding – patients should report any unusual bruising, prolonged bleeding, or blood in urine or stool to their doctor immediately.
- Dose adjustments are required for patients with reduced kidney function, low body weight (60 kg or less), or those taking certain P-glycoprotein inhibitors.
What Is Edoxaban Krka and What Is It Used For?
Quick Answer: Edoxaban Krka is a prescription blood-thinning medication (anticoagulant) that prevents harmful blood clots. It belongs to the class of direct oral anticoagulants (DOACs) and works by blocking factor Xa, a key enzyme in the blood clotting process.
Edoxaban Krka contains the active substance edoxaban, which is a highly selective, direct, and reversible inhibitor of coagulation factor Xa. Factor Xa plays a central role in the blood coagulation cascade, and by inhibiting this enzyme, edoxaban effectively reduces thrombin generation and prevents the formation of harmful blood clots (thrombi). This mechanism of action differs fundamentally from older anticoagulants like warfarin, which work by blocking vitamin K-dependent clotting factors.
The medication is approved for two primary indications. First, it is used for the prevention of stroke and systemic embolism in adult patients with non-valvular atrial fibrillation (NVAF) who have one or more risk factors. Atrial fibrillation is a common heart rhythm disorder in which the upper chambers of the heart (atria) beat irregularly and often too rapidly, creating conditions that favor the formation of blood clots. If these clots travel to the brain, they can cause a stroke. The landmark ENGAGE AF-TIMI 48 trial, which enrolled over 21,000 patients, demonstrated that edoxaban was non-inferior to warfarin for stroke prevention while causing significantly less major bleeding.
Second, Edoxaban Krka is indicated for the treatment of deep vein thrombosis (DVT) and pulmonary embolism (PE), as well as for the prevention of recurrent DVT and PE in adults. DVT occurs when a blood clot forms in a deep vein, usually in the legs, while PE is a potentially life-threatening condition in which a blood clot travels to the lungs. The Hokusai-VTE trial demonstrated that edoxaban was non-inferior to standard warfarin therapy for treating these conditions, with a significantly lower rate of clinically relevant bleeding.
Edoxaban Krka is a generic medicine, meaning it contains the same active substance and works in the same way as the original reference product (Lixiana). It has been authorized through the European Medicines Agency (EMA) decentralized procedure and meets the same rigorous quality, safety, and efficacy standards as the originator product. As a generic medication, it offers an important option for healthcare systems seeking to provide high-quality anticoagulation therapy at a more accessible cost.
It is important to note that edoxaban is not recommended for patients with mechanical heart valves or moderate-to-severe mitral stenosis, as the evidence base for these conditions is insufficient. Additionally, it should not be used in patients with a creatinine clearance (CrCl) greater than 95 mL/min due to an observed increased risk of ischemic stroke compared to warfarin in this population subgroup from the ENGAGE AF-TIMI 48 trial.
What Should You Know Before Taking Edoxaban Krka?
Quick Answer: Before starting Edoxaban Krka, your doctor must assess your kidney function, bleeding risk, and current medications. This medicine is not suitable for everyone, and several important contraindications and precautions must be carefully evaluated.
Contraindications
Edoxaban Krka must not be taken in the following situations:
- Hypersensitivity to edoxaban or any of the excipients contained in the tablet
- Clinically significant active bleeding – including gastrointestinal hemorrhage, intracranial bleeding, or any other active pathological bleeding
- Hepatic disease associated with coagulopathy and clinically relevant bleeding risk, including patients with cirrhosis classified as Child-Pugh B or C
- Uncontrolled severe hypertension that significantly increases the risk of hemorrhagic events
- Concomitant treatment with any other anticoagulant agent (e.g., unfractionated heparin, low-molecular-weight heparins, warfarin, or other DOACs), except when switching anticoagulant therapy or when unfractionated heparin is given at doses necessary to maintain a patent central venous or arterial catheter
- Pregnancy and breastfeeding (see section below)
- Lesions or conditions at significant risk of major bleeding, such as current or recent gastrointestinal ulceration, presence of malignant neoplasms at high risk of bleeding, recent brain or spinal injury/surgery, recent intracranial hemorrhage, known or suspected esophageal varices, arteriovenous malformations, vascular aneurysms, or major intraspinal or intracerebral vascular abnormalities
Warnings and Precautions
Several important warnings and precautions apply to the use of Edoxaban Krka. Your doctor should carefully evaluate your individual risk-benefit profile before initiating treatment.
Edoxaban Krka increases the risk of bleeding, which can be serious and potentially fatal. The risk is elevated in patients taking concomitant antiplatelet drugs, NSAIDs, or other medications that affect hemostasis. Signs of bleeding may include unexplained bruising, prolonged nosebleeds, blood in urine or stool, vomiting blood, or unusually heavy menstrual bleeding. Seek immediate medical attention if you experience any of these symptoms.
Kidney function: Renal function should be assessed before starting treatment and should be monitored regularly thereafter, particularly in situations where kidney function may decline (e.g., dehydration, concurrent nephrotoxic drugs, advancing age). Edoxaban exposure is increased in patients with impaired renal function. A dose reduction to 30 mg once daily is required for patients with a CrCl of 15–50 mL/min. Edoxaban is not recommended in patients with end-stage renal disease (CrCl less than 15 mL/min) or on dialysis. Paradoxically, edoxaban is also not recommended in NVAF patients with high creatinine clearance (greater than 95 mL/min) due to reduced efficacy observed in this subgroup.
Liver function: Patients with severely impaired hepatic function (Child-Pugh C) or with liver disease associated with coagulopathy should not use edoxaban. Patients with mildly or moderately impaired liver function (Child-Pugh A or B) should be treated with caution. Liver function tests should be performed before initiating therapy.
Surgical procedures: If surgery or invasive procedures are planned, edoxaban should be discontinued at least 24 hours before the procedure. If the procedure cannot be delayed, the increased risk of bleeding should be weighed against the urgency of intervention. Edoxaban should be restarted as soon as adequate hemostasis has been established, recognizing that the time to onset of the anticoagulant effect is approximately 1–2 hours.
Spinal/epidural anesthesia: Patients receiving neuraxial (spinal/epidural) anesthesia or undergoing spinal puncture are at risk of developing epidural or spinal hematomas, which may result in long-term or permanent paralysis. The risk is increased by the use of indwelling epidural catheters and concomitant use of drugs affecting hemostasis. Edoxaban should be discontinued at least 12 hours before spinal/epidural puncture or catheter removal.
Premature discontinuation of any oral anticoagulant, including edoxaban, in the absence of adequate alternative anticoagulation increases the risk of thrombotic events such as stroke. If edoxaban must be discontinued for a reason other than pathological bleeding or completion of therapy, consider coverage with another anticoagulant as directed by your healthcare provider.
Pregnancy and Breastfeeding
Edoxaban Krka is contraindicated during pregnancy. Animal studies have shown reproductive toxicity, and the potential risk to humans is unknown. Women of childbearing potential should use effective contraception during treatment. If pregnancy occurs during treatment, the medication should be discontinued immediately and the patient should consult their doctor.
It is not known whether edoxaban or its metabolites are excreted in human breast milk. Animal data indicate that edoxaban is excreted in milk. Therefore, breastfeeding is not recommended during treatment with Edoxaban Krka. A decision must be made whether to discontinue breastfeeding or to discontinue therapy, taking into account the benefit of breastfeeding for the child and the benefit of therapy for the mother.
Fertility: No specific studies on the effect of edoxaban on human fertility have been conducted. Animal studies showed no direct or indirect harmful effects with respect to fertility.
How Does Edoxaban Krka Interact with Other Drugs?
Quick Answer: Edoxaban interacts primarily through the P-glycoprotein (P-gp) transporter pathway. Drugs that inhibit P-gp can increase edoxaban levels, while P-gp inducers may reduce its effectiveness. Concomitant use with other anticoagulants, antiplatelet agents, or NSAIDs increases bleeding risk.
Edoxaban is primarily absorbed from the gastrointestinal tract and is a substrate for the P-glycoprotein (P-gp) efflux transporter. Unlike some other DOACs, edoxaban has minimal interaction with cytochrome P450 enzymes, which somewhat simplifies its drug interaction profile. However, several clinically significant interactions must still be carefully managed.
The P-gp transporter plays a key role in the absorption and elimination of edoxaban. Drugs that inhibit P-gp can increase plasma concentrations of edoxaban, potentially increasing the risk of bleeding. Conversely, strong P-gp inducers can decrease edoxaban exposure, potentially reducing its anticoagulant efficacy. The following table summarizes the most important drug interactions.
Major Interactions
| Interacting Drug | Effect on Edoxaban | Clinical Recommendation |
|---|---|---|
| Cyclosporine | Increases edoxaban levels by ~73% (P-gp inhibition) | Reduce dose to 30 mg once daily |
| Dronedarone | Increases edoxaban levels by ~85% (P-gp inhibition) | Reduce dose to 30 mg once daily |
| Erythromycin | Increases edoxaban levels by ~85% (P-gp inhibition) | Reduce dose to 30 mg once daily |
| Ketoconazole | Increases edoxaban levels by ~87% (P-gp inhibition) | Reduce dose to 30 mg once daily |
| Warfarin / Other anticoagulants | Additive anticoagulant effect | Concomitant use is contraindicated |
| Rifampicin | Decreases edoxaban levels by ~34% (P-gp induction) | Avoid concomitant use; reduced efficacy |
| Phenytoin / Carbamazepine | May decrease edoxaban levels (P-gp induction) | Avoid concomitant use if possible |
| St. John’s Wort | May decrease edoxaban levels (P-gp induction) | Avoid concomitant use |
Interactions Requiring Monitoring
| Interacting Drug | Effect | Clinical Recommendation |
|---|---|---|
| Aspirin (low-dose) | Increased bleeding risk | Use with caution; monitor for signs of bleeding |
| Clopidogrel / Prasugrel | Increased bleeding risk (antiplatelet + anticoagulant) | Use only if clearly indicated; close monitoring |
| NSAIDs (ibuprofen, naproxen) | Increased bleeding risk, especially GI bleeding | Avoid chronic NSAID use; short-term use with caution |
| SSRIs / SNRIs | Increased bleeding tendency | Monitor for signs of bleeding |
| Verapamil | Increases edoxaban levels by ~53% | No dose adjustment required; monitor clinically |
| Amiodarone | Increases edoxaban levels by ~40% | No dose adjustment required; monitor clinically |
| Quinidine | Increases edoxaban levels by ~77% | No dose adjustment required; monitor clinically |
Edoxaban does not inhibit or induce cytochrome P450 enzymes (CYP1A2, CYP2A6, CYP2B6, CYP2C8/9, CYP2C19, CYP2D6, CYP2E1, CYP3A4/5) at clinically relevant concentrations. This means edoxaban is unlikely to alter the metabolism of drugs that rely on these enzyme pathways, which is an advantage compared to some other DOACs that have more extensive CYP-mediated interactions.
Food interactions: Edoxaban can be taken with or without food. There are no dietary restrictions required, which is a significant advantage over warfarin, where vitamin K-rich foods can affect anticoagulation control.
What Is the Correct Dosage of Edoxaban Krka?
Quick Answer: The standard adult dose is 60 mg once daily. A reduced dose of 30 mg once daily is required for patients with moderate-to-severe kidney impairment, low body weight (60 kg or less), or those taking certain P-glycoprotein inhibitors. The 15 mg tablet is used during the transition from higher doses or for specific clinical scenarios.
Adults
For the prevention of stroke and systemic embolism in non-valvular atrial fibrillation, the recommended dose is 60 mg once daily. Treatment should be continued long-term as directed by the prescribing physician.
For the treatment of DVT and PE, the recommended dose is 60 mg once daily following initial use of a parenteral anticoagulant (such as heparin) for at least 5 days. The total duration of treatment (parenteral plus oral) should be based on the clinical situation and relevant guidelines, typically a minimum of 3 months.
Dose Reduction to 30 mg Once Daily
The dose must be reduced to 30 mg once daily in patients with one or more of the following clinical factors:
- Moderate or severe renal impairment (CrCl 15–50 mL/min)
- Low body weight of 60 kg or less
- Concomitant use of the P-gp inhibitors cyclosporine, dronedarone, erythromycin, or ketoconazole
| Indication | Standard Dose | Reduced Dose | Duration |
|---|---|---|---|
| NVAF – Stroke prevention | 60 mg once daily | 30 mg once daily | Long-term |
| DVT treatment | 60 mg once daily (after 5+ days parenteral) | 30 mg once daily | Minimum 3 months |
| PE treatment | 60 mg once daily (after 5+ days parenteral) | 30 mg once daily | Minimum 3 months |
| DVT/PE prevention (recurrent) | 60 mg once daily | 30 mg once daily | As determined by physician |
Children and Adolescents
The safety and efficacy of Edoxaban Krka in children and adolescents below 18 years of age have not been established. No data are available. Therefore, edoxaban is not recommended for use in the pediatric population.
Elderly Patients
No dose adjustment is required based on age alone. However, elderly patients are more likely to have reduced renal function, lower body weight, and to be taking interacting medications, all of which may necessitate dose reduction. The prescribing physician should assess the overall clinical profile of the elderly patient, with particular attention to renal function monitoring, which should be conducted at least annually in patients over 75 years of age and more frequently in those with borderline renal function.
Missed Dose
If a dose is missed, it should be taken as soon as remembered on the same day. The patient should not take a double dose on the same day to make up for a forgotten dose. If the missed dose cannot be taken on the same day, the patient should simply skip it and resume the normal dosing schedule the following day. Consistency in daily dosing is important for maintaining effective anticoagulation.
Overdose
Overdose with edoxaban may lead to hemorrhagic complications due to excessive anticoagulation. There is no specific approved reversal agent. In clinical trials, the use of 4-factor prothrombin complex concentrate (4F-PCC) has been shown to reverse the anticoagulant effects of edoxaban. Andexanet alfa, a recombinant modified human factor Xa protein, has also been studied for reversal of factor Xa inhibitors.
In the event of overdose, standard supportive measures should be initiated, including monitoring for bleeding. Hemodialysis does not significantly contribute to edoxaban clearance (approximately 9% removed in 4 hours). Activated charcoal may be considered if the overdose has been recent (within 2 hours). Patients who overdose should seek immediate medical attention and be managed in a healthcare facility with appropriate monitoring capabilities.
What Are the Side Effects of Edoxaban Krka?
Quick Answer: The most common side effects of Edoxaban Krka are bleeding-related events, including skin and soft tissue bleeding, epistaxis (nosebleeds), and vaginal bleeding. Anemia, rash, and abnormal liver function tests are also commonly reported. Serious bleeding events, while less common, require immediate medical attention.
Like all medicines, Edoxaban Krka can cause side effects, although not everybody gets them. The most clinically significant adverse effect is bleeding, which is inherent to the mechanism of action of all anticoagulants. The ENGAGE AF-TIMI 48 and Hokusai-VTE trials provide comprehensive safety data based on over 21,000 patients treated with edoxaban. The following categorization of side effects is based on their frequency as observed in clinical trials.
Very Common
Affects more than 1 in 10 people
- Skin and soft tissue bleeding (bruising, ecchymosis)
Common
Affects 1 to 10 in 100 people
- Epistaxis (nosebleeds)
- Vaginal bleeding (in women)
- Gastrointestinal bleeding (oral, upper GI, lower GI, rectal)
- Hematuria (blood in urine)
- Bleeding following procedures or at injection sites
- Anemia
- Rash and pruritus (itching)
- Elevated liver enzymes (ALT, AST, GGT, bilirubin)
- Headache
- Dizziness
- Abdominal pain
- Nausea
Uncommon
Affects 1 to 10 in 1,000 people
- Intracranial hemorrhage (bleeding in the brain)
- Conjunctival/scleral hemorrhage (bleeding in the eye)
- Intraocular bleeding
- Hemoptysis (coughing up blood)
- Allergic reactions (urticaria, angioedema)
- Thrombocytopenia (low platelet count)
- Elevated alkaline phosphatase
- Elevated blood bilirubin
Rare
Affects 1 to 10 in 10,000 people
- Anaphylactic reaction
- Subarachnoid hemorrhage
- Pericardial hemorrhage
- Retroperitoneal hemorrhage
- Intramuscular bleeding (without compartment syndrome)
- Intra-articular bleeding (joint bleeding)
- Subdural hemorrhage
Contact your doctor or go to the emergency department immediately if you experience: severe or uncontrollable bleeding; blood in your vomit or vomit that looks like coffee grounds; red or black tarry stools; coughing up blood; sudden severe headache, confusion, weakness on one side of the body, or vision/speech changes (possible intracranial bleeding); severe abdominal pain; or signs of a severe allergic reaction (difficulty breathing, facial swelling, hives).
The rate of major bleeding with edoxaban 60 mg was 2.75% per year in the ENGAGE AF-TIMI 48 trial compared to 3.43% per year with warfarin, representing a statistically significant 20% relative risk reduction. The rate of intracranial hemorrhage was 0.39% per year with edoxaban versus 0.85% per year with warfarin, a 53% relative reduction. This significantly lower rate of intracranial hemorrhage is considered one of the most clinically meaningful advantages of edoxaban over warfarin.
Gastrointestinal bleeding was observed at similar or slightly higher rates with edoxaban 60 mg compared to warfarin in the ENGAGE AF-TIMI 48 trial. Patients with a history of gastrointestinal bleeding should be treated with caution, and the prescribing physician should weigh the risk of GI bleeding against the benefits of anticoagulation.
How Should You Store Edoxaban Krka?
Quick Answer: Store Edoxaban Krka at room temperature (below 30°C), in the original packaging to protect from moisture. Keep out of the reach of children. Do not use after the expiry date.
Edoxaban Krka film-coated tablets should be stored at temperatures not exceeding 30°C (86°F). The tablets should be kept in the original blister packaging to protect them from moisture, as edoxaban is sensitive to humidity. Do not remove tablets from the blister until you are ready to take them.
Keep this medicine out of the sight and reach of children. Accidental ingestion by a child can cause serious bleeding complications and constitutes a medical emergency.
Do not use Edoxaban Krka after the expiry date stated on the carton and blister after “EXP.” The expiry date refers to the last day of that month. Do not use this medicine if you notice any visible signs of deterioration, such as discoloration or damaged tablets.
Do not dispose of medicines via wastewater or household waste. Ask your pharmacist how to dispose of medicines you no longer use. Proper disposal helps protect the environment and prevents accidental exposure to others.
What Does Edoxaban Krka Contain?
Quick Answer: Each film-coated tablet contains edoxaban tosilate monohydrate equivalent to 15 mg of edoxaban as the active substance, along with standard pharmaceutical excipients.
The active substance is edoxaban (as tosilate monohydrate). Each film-coated tablet contains edoxaban tosilate monohydrate equivalent to 15 mg of edoxaban. Edoxaban tosilate monohydrate is the salt form used to ensure adequate solubility and bioavailability of the drug.
Tablet core excipients: The inactive ingredients in the tablet core typically include mannitol, pregelatinized starch, crospovidone, hydroxypropyl cellulose, magnesium stearate, and sodium lauryl sulfate. These excipients serve various functions: mannitol and pregelatinized starch act as fillers and binders, crospovidone as a disintegrant to ensure the tablet breaks apart in the gastrointestinal tract, hydroxypropyl cellulose as a binder, magnesium stearate as a lubricant during manufacturing, and sodium lauryl sulfate as a wetting agent to improve dissolution.
Film-coating: The film coat contains hypromellose, titanium dioxide (E171), talc, iron oxide red (E172), and iron oxide yellow (E172). The film coat provides physical protection for the tablet, aids in swallowing, and gives the tablet its characteristic appearance. The 15 mg tablet is typically an orange, round, film-coated tablet.
Important information about excipients: This medicine contains sodium lauryl sulfate. Patients with known hypersensitivity to any of the listed excipients should not take this medicine. If you have concerns about any of the ingredients, discuss them with your pharmacist or doctor.
Frequently Asked Questions About Edoxaban Krka
Edoxaban Krka is a direct oral anticoagulant (blood thinner) used for two main purposes: preventing stroke and systemic embolism in adults with non-valvular atrial fibrillation (an irregular heartbeat), and treating and preventing recurrent deep vein thrombosis (blood clots in the legs) and pulmonary embolism (blood clots in the lungs). It works by inhibiting factor Xa, a key enzyme in the blood clotting process.
Edoxaban Krka offers several practical advantages over warfarin. It does not require regular blood monitoring (INR tests), has a more predictable anticoagulant effect, has fewer food interactions (no dietary restrictions on vitamin K-rich foods), reaches its full therapeutic effect within 1–2 hours, and is taken as a fixed once-daily dose. Additionally, clinical trials showed that edoxaban causes significantly less intracranial hemorrhage compared to warfarin.
Yes, Edoxaban Krka can be taken with or without food. Food does not significantly affect the absorption or efficacy of the medication. Take the tablet once daily at approximately the same time each day, swallowed whole with water. There are no dietary restrictions, unlike warfarin which requires consistent vitamin K intake.
If you miss a dose, take it as soon as you remember on the same day. Do not take two doses on the same day to make up for a missed one. If you cannot take the missed dose on the same day, simply skip it and take your next dose at the regular time the following day. If you are unsure about what to do, contact your doctor or pharmacist for advice.
There is no specific widely approved antidote for edoxaban. However, andexanet alfa (marketed as Andexxa or Ondexxya) has been approved in some regions for reversing factor Xa inhibitors during life-threatening bleeding. In emergency situations, doctors may use prothrombin complex concentrate (PCC) or activated PCC to help restore clotting. Hemodialysis does not significantly remove edoxaban. If you suspect an overdose, seek emergency medical care immediately.
While there is no specific contraindication against moderate alcohol consumption with edoxaban, excessive alcohol intake should be avoided. Heavy or chronic alcohol use can impair liver function, which affects blood clotting and may increase the risk of bleeding. Alcohol can also increase the risk of falls, which is particularly dangerous when taking anticoagulants. Discuss your alcohol consumption with your doctor for personalized advice.
References
This article is based on the following peer-reviewed sources, clinical guidelines, and regulatory documents:
- Giugliano RP, Ruff CT, Braunwald E, et al. Edoxaban versus Warfarin in Patients with Atrial Fibrillation. N Engl J Med. 2013;369(22):2093-2104. doi:10.1056/NEJMoa1310907 (ENGAGE AF-TIMI 48 trial)
- Hokusai-VTE Investigators, Büller HR, Décousus H, et al. Edoxaban versus Warfarin for the Treatment of Symptomatic Venous Thromboembolism. N Engl J Med. 2013;369(15):1406-1415. doi:10.1056/NEJMoa1306638
- European Medicines Agency (EMA). Edoxaban – Summary of Product Characteristics. Last updated 2024. Available at: ema.europa.eu
- Hindricks G, Potpara T, Dagres N, et al. 2020 ESC Guidelines for the diagnosis and management of atrial fibrillation. Eur Heart J. 2021;42(5):373-498. doi:10.1093/eurheartj/ehaa612
- Konstantinides SV, Meyer G, Becattini C, et al. 2019 ESC Guidelines for the diagnosis and management of acute pulmonary embolism. Eur Heart J. 2020;41(4):543-603.
- National Institute for Health and Care Excellence (NICE). Edoxaban for treating and for preventing deep vein thrombosis and pulmonary embolism. Technology appraisal guidance [TA354]. 2015 (updated 2023).
- Ruff CT, Giugliano RP, Braunwald E, et al. Comparison of the efficacy and safety of new oral anticoagulants with warfarin in patients with atrial fibrillation: a meta-analysis of randomised trials. Lancet. 2014;383(9921):955-962.
- World Health Organization (WHO). WHO Model List of Essential Medicines – 23rd List. 2023. Geneva: World Health Organization.
- Connolly SJ, Milling TJ Jr, Eikelboom JW, et al. Andexanet Alfa for Acute Major Bleeding Associated with Factor Xa Inhibitors. N Engl J Med. 2016;375(12):1131-1141.
- British National Formulary (BNF). Edoxaban tosilate. National Institute for Health and Care Excellence (NICE). Accessed January 2026.
Editorial Team
This article has been written and reviewed by the iMedic Medical Editorial Team, comprising licensed physicians with specialist training in cardiology, hematology, and internal medicine.
Board-certified physicians specializing in cardiovascular medicine and anticoagulation therapy. All content follows the GRADE evidence framework and is based on systematic reviews and randomized controlled trials.
Independent review panel ensuring accuracy, completeness, and adherence to international clinical guidelines (ESC, EMA, NICE, WHO). All claims are verified against primary sources.
Editorial Standards: All medical content on iMedic is produced independently without commercial funding or pharmaceutical sponsorship. We follow strict editorial standards to ensure accuracy and transparency. Our content is reviewed at least annually and updated whenever new evidence or guideline changes warrant revision.